Key Insights

Highlights

Success Rate

75% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 77/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

75.0%

-11.5% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed with results

Key Signals

75% success

Data Visualizations

Phase Distribution

3Total

Not Applicable (1)

P 2 (1)

P 3 (1)

Trial Status

Completed3

Terminated1

Trial Success Rate

75.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (4)

Showing 4 of 4 trials

NCT04302233Not ApplicableCompletedPrimary

A Randomized Study of Superiority of POSToperative Pharmaceutical Support on Patients' Knowledge of Their IMPlant

NCT03123289Phase 2TerminatedPrimary

Novel Gallium 68 Citrate in Orthopedic Infections

NCT02177097Completed

Chronic Pain, Inflammation and Infection After Joint Replacement

NCT00211926Phase 3Completed

StaphVAX Immunogenicity in Orthopedic Implant Patients

Showing all 4 trials

Joint Prosthesis